Firefly Bio Debuts With $94 Million Series A Financing
02/15/24, 1:10 PM
Location
san franciscoMoney raised
$94 million
Industry
biotechnology
health care
Round Type
series a
Investors
Eli Lilly & Company, Decheng Capital, Mpm Bio Impact, Versant Ventures
Firefly Bio emerged from stealth mode with a $94 million Series A financing co-led by founding investor Versant Ventures and by MPM BioImpact alongside Decheng Capital and with participation from Eli Lilly & Company.
Company Info
Location
san francisco, california, united states
Additional Info
Firefly Bio is a biotech company focused on developing a novel platform to treat cancer using degrader antibody conjugates (DACs). The company aims to precisely drug a range of intracellular biological targets that were previously hampered by therapeutic index issues when delivered systemically.